At the center of medical innovation, Medtech CDMOs are powering growth through strategic M&A, rising venture capital interest and next-gen technologies. With growing demand for AI-enabled devices and minimally invasive solutions, the sector is evolving rapidly, particularly in the U.S., where market momentum outpaces Europe’s more fragmented landscape. As regulatory complexity increases, CDMOs are becoming essential partners for first-time launches and scalable growth.
What You'll Learn:
- Market dynamics driven by M&A activity, including major deals like J&J’s acquisition of Shockwave and V-Wave
- Growth areas fueled by venture capital, AI and minimally invasive technologies
- The expanding role of CDMOs in regulatory support and commercialization
- U.S. market strength versus European structural hurdles and consolidation potential
- Capital market insights, from IPOs to private equity opportunities
Medtech CDMOs offer a compelling opportunity for investors, operators and innovators to accelerate advancement in the healthcare ecosystem.
Download the Report
Navigating Global Pharma Policy
September 29, 2025
As the U.S. considers imposing tariffs on European pharmaceutical imports, the ripple effects could be felt across the global healthcare landscape. For an industry already grappling with rising R&D costs and competitive pressures, these tariffs threaten to erode profit margins and disrupt finely tuned supply chains.
What if the biosimilar wave is just a ripple?
September 9, 2025
As biologics face a record-breaking patent cliff, the anticipated biosimilar wave may be more of a ripple than a wave. To thrive, life sciences firms must shift from solely pursuing speed to mastering precision.
ALVAREZ & MARSAL BOLSTERS ITS HEALTHCARE PRACTICE IN SOUTHEAST ASIA (ASEAN) REGION WITH THE APPOINTMENT OF SANATH KUMAR AS MANAGING DIRECTOR
September 1, 2025
Leading global professional services firm Alvarez & Marsal (A&M) has announced the appointment of Sanath Kumar as Managing Director within its Southeast Asia and Australia (SEAA) business unit. Based in Singapore, Mr. Sanath will play a strategic role in building out A&M’s Healthcare and Life Sciences practice across ASEAN markets.
Next-Generation Antibodies: A New Era in Immuno-Oncology
August 25, 2025
As the immune checkpoint inhibitor (ICI) market nears a patent cliff, the $50B immuno-oncology (IO) field is now seeking to surpass the limitations of earlier ICIs by enhancing survival outcomes, broadening coverage, and overcoming resistance mechanisms.
